NCT07219589 - A SAD Study of HM17321 in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

ObesityObese

Interventions

DRUG

HM17321

Participants will receive a single subcutaneous injection of HM17321 at the assigned dose level. HM17321 is provided as a sterile solution in prefilled syringes.

DRUG

Placebo of HM17321

Participants will receive a single subcutaneous injection of a matching placebo solution in prefilled syringes. The placebo does not contain any active ingredients.

Trial Locations (1)

45227

Medpace Clinical Pharmacology Unit, Cincinnati